1. Home
  2. IRTC vs ACAD Comparison

IRTC vs ACAD Comparison

Compare IRTC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iRhythm Technologies Inc.

IRTC

iRhythm Technologies Inc.

HOLD

Current Price

$169.94

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$27.04

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRTC
ACAD
Founded
2006
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
4.6B
IPO Year
2016
2004

Fundamental Metrics

Financial Performance
Metric
IRTC
ACAD
Price
$169.94
$27.04
Analyst Decision
Strong Buy
Buy
Analyst Count
14
22
Target Price
$203.93
$29.05
AVG Volume (30 Days)
454.2K
1.4M
Earning Date
10-30-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.53
EPS
N/A
1.54
Revenue
$702,573,000.00
$1,047,118,000.00
Revenue This Year
$27.20
$15.16
Revenue Next Year
$16.89
$11.42
P/E Ratio
N/A
$17.62
Revenue Growth
25.45
12.69
52 Week Low
$84.17
$13.40
52 Week High
$212.00
$27.73

Technical Indicators

Market Signals
Indicator
IRTC
ACAD
Relative Strength Index (RSI) 38.34 69.78
Support Level $166.76 $26.38
Resistance Level $187.98 $27.73
Average True Range (ATR) 6.55 0.83
MACD -1.41 0.14
Stochastic Oscillator 9.08 88.00

Price Performance

Historical Comparison
IRTC
ACAD

About IRTC iRhythm Technologies Inc.

iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: